Video
Dr. Davies discusses data from CheckMate-274 study of nivolumab in urothelial carcinoma
Author(s):
"I think that for patients that have high-risk features after cystectomy, they absolutely should be on nivolumab. I don't think that's a controversial statement anymore," says Benjamin J. Davies, MD.
Video Player is loading.
In this video, Benjamin J. Davies, MD, discusses findings from the study, Disease-free survival with longer follow-up from the CheckMate-274 trial of adjuvant nivolumab in patients after surgery for high-risk muscle-invasive urothelial carcinoma, which was presented at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana. Davies is a professor of urology at the University of Pittsburgh School of Medicine, chief of urology at UPMC Shadyside, and program director of the Urologic Oncology Fellowship.
Related Videos
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Considerations for patient follow-up after onabotA administration
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Administering onabotA: Improving patient comfort and easing anxiety
Expert discusses genitourinary syndrome of menopause guidelines
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Joshua Heiman, MD, on phentermine plus topiramate for uric acid stone prevention
Amy Krambeck, MD, on innovation and building strong programs in endourology
Investigators evaluate patient outcomes with silicone vs polyurethane stents
Related Content
